Do you suffer from dry eye? Stick this up your nose.

Allergan received FDA approval to market their new dry eye treatment device,TrueTear.

What is it?
It’s a handheld intranasal neurostimulator that provides a temporary increase in tear production during neurostimulation but can last up to four hours.
Here is a picture.

Tell me about the clinical studies.
There were two. The first one was a one day study with 48 patients. The second study contained 97 patients that were followed over a 6 month period. Schirmer testing was measured during stimulation and both studies found an increase in tear production with TrueTear.
More study details here. Good rundown by Jenn here.

How do you use it?
TrueTear is placed in the nasal cavity and emits micro-electric pulses to stimulate the lacrimal gland and trigeminal nerve. The intensity can be adjusted but the desired effect is to a feel a “tingling sensation” in the nose. The neurostimulation should be no longer than 3 minutes at a time and no more than 10 times a day.

Any adverse events?
No. The main side effect was nasal discomfort.

Is this covered by insurance?
There is no information on how much it will cost or if it will be covered by insurance but you will need a prescription to purchase it.

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Optometry Podcast: Transitions® The Pulse, Feel the Love for Eyecare

Transitions® The Pulse will bring together eyecare industry professionals from over 42 countries with the first of its’ kind global virtual industry event on February 9th, 2021. “We’re gathering together to build that collective strength to help our businesses thrive and prosper in 2021,” King shares about the inspiration behind the event.

Latest Posts